BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 27, 2011
 |  BioCentury  |  Politics, Policy & Law

Talking capital in the Capitol

BIO releases proposals for tax, other incentives to boost biotech investment

Alongside its agenda for regulatory reform this week, BIOwill roll out a series of proposals for tax law and other financial legislation to bolster biotech capital formation.

Although BIO is working with members of Congress to have its capital formation proposals introduced as part of broader legislation that would include its regulatory innovation platform, the tax and finance elements will have to be enacted separately, probably as part of tax reform initiatives (see "Progressive Thinking for FDA," A12).

Several of the capital formation proposals are aimed at making it attractive to invest in early stage companies.

"There is a crisis in the innovation ecosystem around emerging biotech companies," Jonathan Leff told BioCentury. "The financing for development stage biotech is becoming much more constrained and difficult to access at precisely the time when it is costing more money and taking longer to develop drugs."

Leff is managing director for healthcare at Warburg Pincus LLC, a member of BIO's board of directors and chairman of the Medical Industry Group of...

Read the full 823 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >